Suven Life Sciences
Market cap ₹7,506 Cr
- P/E
- 13.73
- Day range
- ₹263.45 – ₹270.00
- 52-week range
- ₹124.11 – ₹403.35
- Volume
- 1.41 L
- Open
- ₹269.00
- Prev close
- ₹268.65
Latest results · Q2 FY27(consolidated)Revenue ₹1 Cr+30.4%Profit ₹-107 CrMargin -8922.3%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
65.47%, down 4.68 pts since 2026-03-06 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
SUVEN in NSE indices and F&O
Research profile
Composite 32 / 100Factor percentiles
Derived metrics
- Earn. yield
- 7.3%
- ROE ÷ P/B
- -4.7%
- 12-1 mom.
- +62.0%
- Return / vol
- 0.75
- Magic Formula
- #389
- Piotroski
- 2/6
- FCF yield
- -4.0%
Appears in 9 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Suven Life SciencesSUVEN | ₹7,506 Cr | 13.73 | 16.81 | -78.7% | -80.0% | -9242.0% | 0.04 | 0.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 10h agoHeadlines about Suven Life Sciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- Price / Book
- 16.60
- ROE (FY26)
- -78.7%
- ROCE (latest year)
- -80%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹269.66
- Price below
- 50-day
- ₹303.11
- Price below
- 200-day
- ₹255.5
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | 1 |
| YoY Sales growth | -18 | -8 | -73 | -16 | -34 | -38 | — | -64 | — | — | — | — |
| Expenses | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 | 112 |
| Operating Profit | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 | -111 |
| OPM % | -1885% | -1267% | -3024% | -2032% | -2435% | -2981% | -2714% | -8671% | -3678% | -3331% | -3711% | -9242% |
| Other Income | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| Tax % | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| EPS in Rs | ₹-1.91 | ₹-1.22 | ₹-1.29 | ₹-2.28 | ₹-1.79 | ₹-2.01 | ₹-2.36 | ₹-3.40 | ₹-4.48 | ₹-1.73 | ₹-4.83 | ₹-3.78 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+30 days since Mar 2021
+30 days since Mar 2021
-578 days since Mar 2021
Strengths, risks & growth
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders. [1] [2]
Strengths
- Company is almost debt free.
Risks
- Stock is trading at 16.7 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -4.61%
- The company has delivered a poor sales growth of -12.0% over past five years.
- Company has a low return on equity of -65.9% over last 3 years.
- Debtor days have increased from 63.7 to 77.5 days.
- Working capital days have increased from 55.6 days to 506 days
Compounded Sales Growth
- 10 Years
- -35%
- 5 Years
- -12%
- 3 Years
- -19%
- TTM
- +55%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- -80%
Stock Price CAGR
- 10 Years
- +38%
- 5 Years
- +25%
- 3 Years
- +47%
- 1 Year
- +48%
Return on Equity
- 10 Years
- -24%
- 5 Years
- -68%
- 3 Years
- -66%
- Last Year
- -82%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 67.36% | 70.15% | 70.08% | 65.47% | -4.61 pp |
| FII | 1.07% | 0.91% | 0.56% | 0.45% | -0.11 pp |
| DII | 3.39% | 4.62% | 2.93% | 2.17% | -0.76 pp |
| Public | 28.18% | 24.32% | 26.42% | 31.89% | +5.47 pp |
Filed with NSE for Sept 2026: promoters 65.47%, public 34.53%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 0.08% (+0.07 pp)- Promoters65.5%
- Foreign institutions0.5%
- Mutual funds0.1%
- Insurance0.0%
- Other domestic institutions2.1%
- Retail17.7%
- Others14.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.07% | 0.24% | +0.24 pp |
| Groww Nifty Total Market Index Fund | 0.00% | 0.01% | +0.01 pp |
| Bandhan BSE Healthcare Index Fund | 0.00% | 0.12% | -0.02 pp |
| Aditya Birla SL BSE Total Market Index Fund | 0.00% | 0.01% | +0.01 pp |
| Motilal Oswal BSE 1000 Index Fund | 0.00% | 0.01% | -0.00 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- Low
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 55.6%
- Downside volatility
- 45.0%
- Worst 5% of days
- 4.6%
- Average of that tail
- 5.9%
- Max drawdown (1Y)
- 45.5%
- Below its peak
- 32.2%
Against the market
- Beta vs Nifty 50
- 1.22
- Correlation
- 0.30
- Relative strength (3M)
- -24.1%
- ATR (14)
- 5.0%
Return
- Return 1M
- -12.5%
- Return 3M
- -20.2%
- Return 6M
- +5.2%
- Return 1Y
- +41.8%
- vs 200-day average
- +4.0%
Momentum
- RSI (14)
- 41.1
- MACD histogram
- 2.02
- Stochastic %K
- 25.1
- ADX (14)
- 16.9
- +DI / −DI
- 17.5 / 20.5
- Money flow index
- 54.4
Participation
- Delivery (20d avg)
- 41.1%
- vs its 60-day baseline
- -1.6 pts
- Volume vs 20-day
- -1.3σ
- Close vs day's VWAP
- -0.1%
- 52-week position
- 52 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — failed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- -₹306 Cr
- FCF yield
- -4.0%
- Cash conversion
- 1.09
- Accruals ratio
- 0.040
- Net debt
- -₹8 Cr
- Net debt / equity
- -0.02
- EV / sales
- 833.91
- Capex intensity
- 71.4%
- Revenue CAGR
- 30.4%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Jasti Property and Equity Holdings Private Limited Promoter Group · Conversion of security | Buy | 3,17,68,764 | ₹426 Cr | 10 Mar 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- otherNot available — not reported in this filing
Annual General Meeting
30 Jul 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
2 Aug 2023ex-date - rightsNot available — not reported in this filing
Rights 1:2 @ Premium Rs 54/-
17 Oct 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
29 Jul 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
2 Aug 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
11 Sept 2020ex-date - otherNot available — not reported in this filing
Demerger
21 Jan 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
8 Aug 2019ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
14 Feb 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
9 Aug 2018ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share (Purpose Revised)
6 Feb 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
9 Aug 2017ex-date - dividendNot available — not reported in this filing
Interim Dividend Re 1 Per Share
8 Feb 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
4 Aug 2016ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 1/- Per Share / Special Dividend - Re 1/- Per Share (Purpose Revised)
14 Mar 2016ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.60/- Per Share
23 Jul 2015ex-date - dividend₹2.00
Annual General Meeting /Final Dividend - Re 0.50/- Per Share + Special Dividend - Rs 2/- Per Share
24 Jul 2014ex-date - dividendNot available — not reported in this filing
Annual General Meeting / Dividend - Re.0.30/- Per Equity Share
1 Aug 2013ex-date - dividendNot available — not reported in this filing
Annual General Meeting And Dividend Re.0.30 Per Share
17 Sept 2012ex-date - dividendNot available — not reported in this filing
Annual General Meeting And Dividend Re.0.25 Per Share
1 Aug 2011ex-date
Company announcements
Please find enclosed the Revised News Release of our company
Please find enclosed the News Release of our Company
Please find enclosed News Release of our Company
Monitoring Agency Report for the quarter ended 30th September, 2026
Newspaper publication on Un-audited financial results
Un-audited financial results for the quarter and half year ended 30th September 2026
Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026
Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results ....
Special Window for Re-lodgment of transfer requests of Physical shares
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Please find enclosed the News release
Report of Scrutinizer
Outcome of 37th Annual General Meeting
Monitoring Agency Report for the quarter ended 30th June, 2026
Filed with BSE (scrip 530239); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Adjudication order
Adjudication Order in respect of Suven Life Sciences Limited and 5 others in the matter of Suven Life Sciences Limited
28 Oct 2021Read on SEBI - Order
Order in the matter of Suven Life Sciences Ltd.
27 Apr 2021Read on SEBI
Documents
Annual reports
Earnings calls
- Jul 2021Slides
- Feb 2020Transcript
- Nov 2019TranscriptSlides
- Aug 2019TranscriptSlides
- May 2019TranscriptSlides
- May 2019Slides
Credit ratings
- Rating update · 22 Apr 2020 from crisil
- Rating update · 27 Jan 2020 from crisil
- Rating update · 31 Dec 2019 from care
- Rating update · 6 Nov 2019 from crisil
- Rating update · 14 Oct 2019 from crisil
- Rating update · 2 May 2019 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Suven Life Sciences: common questions
Answered from the figures on this page.